Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Anthrax Vaccine Market Revenue Growth On Track For A 4.1% CAGR Through 2030
The anthrax vaccine market size has demonstrated consistent expansion in recent years. It is projected to increase from $11.77 billion in 2025 to $12.33 billion in 2026, progressing at a compound annual growth rate (CAGR) of 4.7%. The market’s past growth can be attributed to factors such as the significant prevalence of anthrax in livestock, vaccination campaigns initiated by governments, ongoing research in immunology, existing constraints in vaccine production capacity, and a greater understanding of occupational exposure risks.
The anthrax vaccine market is projected to experience consistent expansion in the coming years, with an anticipated growth to $14.49 billion by 2030, driven by a compound annual growth rate (CAGR) of 4.1%. This projected growth during the forecast period can be primarily attributed to factors such as the advancement of recombinant and next-generation vaccines, an increasing need for both human and animal prophylaxis, improvements in vaccine delivery methods, the expansion of biodefense initiatives, and strategic partnerships formed between pharmaceutical companies and defense organizations. Key trends anticipated during this period encompass the development of sophisticated vaccine formulations, the expansion of immunization programs, innovations in cold chain and storage solutions, enhanced biodefense and pandemic preparedness measures, and vaccination initiatives led by governments and militaries.
Get A Free Sample Report With In-Depth Market Insights:
Anthrax Vaccine Market Growth Factors: What’s Supporting Expansion?
The increasing occurrence of infectious diseases is projected to drive the expansion of the anthrax vaccine market in the future. These diseases are ailments brought on by harmful microorganisms like bacteria, viruses, parasites, or fungi, capable of transmitting directly or indirectly between individuals, frequently resulting in symptoms that vary from mild to severe, and occasionally proving fatal, contingent on the specific pathogen and the host’s immune system. Their widespread presence stems from global demographic shifts, urbanization, alterations in environmental conditions and land utilization, and evolving human conduct. While primarily used for protection against anthrax, the anthrax vaccine’s broader applicability in averting other infectious diseases is under investigation, focusing on its immune-stimulating traits and adaptability. For example, data from February 2023, provided by the US-based nonprofit Council on Foreign Relations, indicated that as many as 75% of new or emerging infectious diseases (EIDs) and 60% of established infectious diseases originated from animals (zoonotic). Moreover, globally, zoonotic diseases are responsible for 2.7 million human fatalities and 2.5 billion instances of illness annually. Consequently, the increasing incidence of these diseases is fueling the growth of the anthrax vaccine market.
Anthrax Vaccine Market Segment Breakdown: Which Categories Lead On Revenue?
The anthrax vaccine market covered in this report is segmented –
1) By Vaccine Type: Cell-Free Protective Antigen (PA) Vaccine, Live Attenuated Vaccine
2) By Application Type: Animal Use, Human Use
3) By Distribution Channel: Hospitals, Pharmacies, Other Distribution Channels
Subsegments:
1) By Cell-Free Protective Antigen (PA) Vaccine: Recombinant Protective Antigen (rPA) Vaccine, Adjuvanted rPA Vaccine
2) By Live Attenuated Vaccine: Live Attenuated Bacillus anthracis Vaccine, Genetically Modified Live Attenuated Vaccine
Anthrax Vaccine Market Industry Trends: What’s Reshaping Demand?
Leading companies within the anthrax vaccine market are concentrating on creating innovative solutions and obtaining FDA approvals for their vaccines. This focus ensures the safety, effectiveness, and accessibility of these vaccines for individuals exposed to anthrax. FDA authorization confirms that a vaccine has undergone extensive clinical testing and is proven safe for public consumption, thereby protecting people from potential side effects. For example, in July 2023, Emergent BioSolutions Inc., a US-based biopharmaceutical company, secured approval from the U.S. Food and Drug Administration (FDA) for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted), formerly known as AV7909. This clearance stemmed from data collected during a Phase 2 trial that assessed Cyfendus’s compatibility with antibacterial drugs, and a Phase 3 clinical study that evaluated its immunogenicity and safety in comparison to BioThrax, the earlier anthrax vaccine. Moreover, the development of safer and more potent adjuvants is essential for overcoming problems linked to reactogenicity and improving the overall efficacy of anthrax vaccines.
Anthrax Vaccine Market Leading Players And Competitive Positioning
Major companies operating in the anthrax vaccine market are Emergent BioSolutions Inc., Indian Immunologicals Limited, GC Biopharma, Valneva SE, PharmAthene Inc., Porton Biopharma Limited, Choong Ang Vaccine Laboratories Co. Ltd., Colorado Serum Company Inc., Botswana Vaccine Institute, VECOL S.A., Biological E Limited, Serum Institute of India Pvt. Ltd., Panacea Biotec Ltd., China National Biotec Group, Sinovac Biotech Ltd., Instituto Butantan, Razi Vaccine and Serum Research Institute, Federal State Unitary Enterprise Microgen, KM Biologics Co. Ltd., Haffkine Bio-Pharmaceutical Corporation Ltd.
View The Full Anthrax Vaccine Market Report:
Anthrax Vaccine Market Geographic Landscape: Which Region Leads Industry Growth?
North America was the largest region in the anthrax vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anthrax vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
